What's Happening?
Quest Diagnostics has completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories. This acquisition positions Quest to provide dialysis-related clinical testing to independent dialysis clinics previously served by Spectra Laboratories. Additionally, Quest will begin providing comprehensive dialysis-related laboratory services for Fresenius Medical Care's dialysis centers in the U.S., serving approximately 200,000 patients annually. The transition of services is expected to be completed by early 2026, allowing Quest to leverage its clinical leadership and diagnostic innovation in chronic kidney disease services.
AD
Why It's Important?
The acquisition is significant as it enhances Quest Diagnostics' capabilities in providing essential dialysis-related testing services, which are crucial for managing chronic kidney disease (CKD). CKD affects about 35.5 million people in the U.S., making it one of the most prevalent and costly chronic diseases. By integrating these services, Quest aims to improve the efficiency and speed of test results reporting, benefiting both providers and patients. This move also allows Quest to optimize its laboratory network, potentially reducing costs and improving service delivery during lower-volume hours.
What's Next?
Quest Diagnostics plans to complete the acquisition of select dialysis-related water testing assets by the end of 2025. The company will continue to transition services to its laboratories across the U.S., aiming to enhance service delivery and diagnostic capabilities. The integration process will involve collaboration with Fresenius Medical Care to ensure a seamless transition for patients and providers.
